{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:22:58Z","timestamp":1777634578264,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41375-022-01521-4","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T14:02:24Z","timestamp":1645884144000},"page":"1432-1435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Luspatercept for myelodysplastic syndromes\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam J.","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-2172","authenticated-orcid":false,"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-6779","authenticated-orcid":false,"given":"Mar\u00eda","family":"D\u00edez-Campelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-1197","authenticated-orcid":false,"given":"Carlo","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph G.","family":"Jurcic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-6524","authenticated-orcid":false,"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-5504","authenticated-orcid":false,"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeevan K.","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianwei","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay T.","family":"Backstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"1521_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1521_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1182\/hematology.2020000163","volume":"2020","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Lasho T. Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a focused review. Hematol Am Soc Hematol Educ Program. 2020;2020:460\u20134.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"1521_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ajh.24332","volume":"91","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, et al. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol. 2016;91:492\u20138.","journal-title":"Am J Hematol"},{"key":"1521_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood-2017-07-746446","volume":"131","author":"R Stauder","year":"2018","unstructured":"Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications, and management. Blood. 2018;131:505\u201314.","journal-title":"Blood"},{"key":"1521_CR5","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1097\/HS9.0000000000000314","volume":"3","author":"U Germing","year":"2019","unstructured":"Germing U, Oliva EN, Hiwase D, Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. [Abstract]. Hemasphere. 2019;3:e314.","journal-title":"Hemasphere"},{"key":"1521_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ajh.26090","volume":"96","author":"MM Patnaik","year":"2021","unstructured":"Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T) - \u201c2021 update on diagnosis, risk-stratification, and management\u201d. Am J Hematol. 2021;96:379\u201394.","journal-title":"Am J Hematol."},{"key":"1521_CR7","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","volume":"97","author":"J Broseus","year":"2012","unstructured":"Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97:1036\u201341.","journal-title":"Haematologica"},{"key":"1521_CR8","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Myelodysplastic syndromes. Version 3.2021. 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf. Accessed 3 Nov 2021."},{"key":"1521_CR9","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ajh.23732","volume":"89","author":"KM Attie","year":"2014","unstructured":"Attie KM, Allison MJ, McClure T, Boyd IE, Wilson DM, Pearsall AE, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89:766\u201370.","journal-title":"Am J Hematol"},{"key":"1521_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140\u201351.","journal-title":"N Engl J Med."},{"key":"1521_CR11","unstructured":"US Food and Drug Administration (FDA). FDA approves luspatercept-aamt for anemia in adults with MDS. 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-luspatercept-aamt-anemia-adults-mds. Accessed 3 Nov 2021."},{"key":"1521_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"1521_CR13","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/ccr3.3026","volume":"8","author":"M Divoux","year":"2020","unstructured":"Divoux M, Plocque A, Sevin M, Voillat L, Feugier P, Guerci-Bresler A, et al. Efficacy of lenalidomide in myelodysplastic\/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count. Clin Case Rep. 2020;8:1774\u201380.","journal-title":"Clin Case Rep."},{"key":"1521_CR14","doi-asserted-by":"publisher","unstructured":"Komrokji R, Melody M, Al Ali N, Chan O, Klimek V, Ball BJ, et al. Treatment outcomes for patients with myelodysplastic syndrome\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2021. https:\/\/doi.org\/10.1080\/10428194.2021.1971217.","DOI":"10.1080\/10428194.2021.1971217"},{"key":"1521_CR15","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1111\/bjh.16515","volume":"189","author":"G Antelo","year":"2020","unstructured":"Antelo G, Mangaonkar AA, Coltro G, Buradkar A, Lasho TL, Finke C, et al. Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T). Br J Haematol. 2020;189:e104\u20138.","journal-title":"Br J Haematol."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01521-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T11:06:12Z","timestamp":1651489572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01521-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01521-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,26]]},"assertion":[{"value":"30 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RSK: Advisory board fees from AbbVie, Acceleron, BMS, Geron, Jazz Pharmaceuticals, and Novartis; speakers\u2019 bureau fees from BMS and Jazz Pharmaceuticals. UP: Grant support from Amgen, Janssen Biotech, Merck and Novartis; grant and travel support, and lecture, steering committee, and consulting fees, travel support from Celgene\/BMS; and lecture fees from Novartis. PF: Consulting fees from Celgene. AMZ: Grant support, honoraria, clinical trial committee and consulting fees, from AbbVie, Celgene\/BMS, and Novartis; consulting fees and honoraria from Acceleron, Agios, Astellas. Beyondspring, Cardinal Health, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Seattle Genetics, Syndax, Taiho, and Tyme; grant support from ADC Therapeutics, Astex and Medimmune\/ AstraZeneca; grant support, consulting fees and honoraria from Amgen, Aprea, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Otsuka, Pfizer, Takeda, and Trovagene; honoraria, consulting and clinical trial committee fees from Gilead and Kura; clinical trial committee fees from Geron. GG-M: Grant support and consulting fees from Astex Pharmaceuticals, BMS, Genentech, and Helsinn Healthcare; grant support from AbbVie, Amphivena Therapeutics, Aprea, Curis, Celgene, Forty Seven, H3 Biomedicine, Janssen, Merck, Novartis, and Onconova Therapeutics. GJM: Grant support from Celgene\/BMS and Novartis. VS: Advisory board and lecture fees from Celgene\/BMS; travel support from Janssen Biotech; advisory board fees from Geron, Gilead, Menarini, Novartis, and Takeda Oncology; grant support from Celgene. MD-C: Consulting fees from Celgene\/BMS, Novartis, and Takeda. CF: Grant support, advisory committees, and speaker fees from Celgene\/BMS; advisory committee and speaker fees from Novartis; consultancy from Takeda; advisory board fees from Janssen Pharmaceuticals. JGJ: Grant and travel support, and advisory board fees, AbbVie; grant support from Arog Pharmaceuticals, Astellas Pharma, Forma Therapeutics, Genentech USA, Gilead Sciences, PTC Therapeutics, and Syros Pharmaceuticals; advisory board fees from AstraZeneca; grant support, advisory board fees, and travel support from BMS\/Celgene; grant support and consulting fees from Daiichi Sankyo; end-point committee fees from Novartis. PLG: Grant support from Celgene. MAS: Advisory boards for BMS, Gilead, Novartis, and Pfizer. AED: No competing financial interests. MRS: Steering committee and data and safety monitoring board fees from Celgene; consultancy and advisory for CTI, Geron, Karyopharm, Novartis, Ryvu, Taiho, Takeda, and TG Therapeutics; grant support from Astex, Incyte, Takeda, and TG Therapeutics; and equity in Karyopharm. JKS: Current employment at and equity in BMS. RI: Former employment and current equity in BMS; current employment and equity in Eli Lilly and Company. GZ and XH: Current employment at BMS. JTB: equity in BMS; current employment and equity in Acceleron Pharma. AV: Equity in Stelexis; consultancy and grant support from BMS; consultancy and honoraria from Acceleron Pharma; grant support from Janssen and Medpacto.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}